Development of Cushing Syndrome After Serial In-office Subglottic Steroid Injections.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 34002875.
- Also identified by DOI 10.1002/lary.29622.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In-office subglottic intralesional steroid injections (SILSI) have gained popularity as an adjunct to operating room dilation in the treatment of subglottic stenosis. They are generally thought to have a low risk profile for development of systemic side effects. Here, we present a case of a 55 year old woman who developed symptoms of Cushing syndrome after receiving SILSI, including weight gain, striae, dorsal hump and alopecia. This case illustrates that despite the localized nature of SILSI, there is still a risk of developing systemic effects as a result of the treatment. Laryngoscope, 132:942-943, 2022.
Medical subject headings
- Cushing Syndrome
- Laryngostenosis